Palonosetron as an anti-emetic and anti-nausea agent in oncology

Figures & data

Table 1 Patient perceptions of the most severe side effects of cancer chemotherapy

Rank	1983a	1993b	1995c	1999d
1	Vomiting	Nausea	Nausea	Nausea
2	Nausea	Constantly tired	Loss of hair	Loss of hair
3	Loss of hair	Loss of hair	Vomiting	Constantly tired
4	Thought of coming for treatment	Effect on family	Constantly tired	Vomiting
5	Length of time treatment takes	Vomiting	Having to have injections	Changes in the way things taste

a (Coates et al 1983)

b (Griffin et al 1996)

c (de Boer-Dennert et al 1997)

d (Lindley et al 1999)

Figure 1 Perception vs reality: Healthcare providers’ predictions of incidence, and observed incidence, of nausea and vomiting following chemotherapy (Drawn from data in Grunberg, Deusson et al 2004).

Figure 2 Schematic diagram of vomiting reflex.

Figure 3 Molecular structure of palonosetron hydrochloride.

Figure 4 Percentage of MEC patients achieving complete response rates in the acute, delayed, and overall phases following treatment with palonosetron 0.25 mg or ondansetron 32 mg/dolasetron 100 mg (Drawn from data in Rubenstein et al 2003; Grunberg, Vanden Burgt et al 2004).

Figure 5 Percentage of emesis-free MEC patients in the acute, delayed and overall phases following treatment with palonosetron 0.25 mg or ondansetron 32 mg/dolasetron 100 mg (Drawn from data in Rubenstein et al 2003).

Figure 6 Percentage of nausea-free MEC patients on a daily basis following treatment with palonosetron 0.25 mg or ondansetron 32 mg/dolasetron 100 mg (Drawn from data in Rubenstein et al 2003).

Table 2 Percentage of nausea-free patients in a pooled analysis of patients receiving single infusion of palonosetron 0.25 mg prior to MEC (Decker et al 2006) compared with patients receiving concomitant infusion of palonosetron 0.25 mg + dexamethasone 8 mg (Hajdenberg et al 2006) on Day 1 only.

Study	Day 1	Day 2	Day 3	Day 4	Day 5
Palonosetron (n = 378)	54.5%	54.2%	57.9%	65.3%	77.5%
Palonosetron + dexamethasone (n = 32)	78.1%	81.3%	68.8%	65.6%	78.1%

CoatesAAbrahamSKayeSBOn the receiving end: Patient perception of the side-effects of cancer chemotherapyEur J Cancer Clin Oncol19831920386681766

 PubMedGoogle Scholar

GriffinAMButowPNCoatesASOn the receiving end V: Patient perceptions of the side effects of cancer chemotherapy in 1993Ann Oncol19967189958777177

 PubMed Web of Science ®Google Scholar

de Boer-DennertMde WitRSchmitzPIPatient perceptions of the side effects of chemotherapy: The influence of 5-HT3 antagonistsBr J Cancer1997761055619376266

 PubMed Web of Science ®Google Scholar

LindleyCMcCuneJSThomasonTEPerception of chemotherapy side effects: cancer versus non-cancer patientsCancer Pract19997596510352062

 PubMedGoogle Scholar

GrunbergSMDeusonRRMavrosPIncidence of chemotherapy-induced nausea and emesis after modern antiemeticsCancer20041002261815139073

 PubMed Web of Science ®Google Scholar

RubensteinEBGrallaRJEisenbergPPalonosetron (PALO) compared with ondansetron (OND) or dolasetron (DOL) for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV): Combined results of two phase III trialsProc Am Soc Clin Oncol200322729 A2932

 Web of Science ®Google Scholar

GrunbergSVanden BurgtJBerrySPrevention of delayed nausea and vomiting (D-CINV): Carryover effect analysis of pooled data from 2 phase III studies of palonosetron (PALO)J Clin Oncol200422A8051

 Web of Science ®Google Scholar

DeckerGMDeMeyerESKiskoDLMeasuring the maintenance of daily life activities using the Functional Living Index-Emesis (FLIE) in patients receiving moderately emetogenic chemotherapyJ Support Oncol20064354116444851

 PubMedGoogle Scholar

HajdenbergJGroteTYeeLInfusion of Palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomitingJ Support Oncol200644677117080735

 PubMedGoogle Scholar